TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Presence of Helicobacter pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Non-calcified Plaque Volume in the Coronary Arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: length of stay in PICU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: serum IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of attempts until surfactant is administrated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of the infants' stability during the procedure - saturation, bradycardia, tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunofluorescence staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in glaucomatous damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change From Baseline in the Inflammatory Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Investigator Global Assessment (IGA) Treatment Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in ectocervical permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal Composite Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: major molecular response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MWD change score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage adherence to Rebif
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of HIV viral sequences in T lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peripheral Neuropathy Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain Scale (S-LANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aseptic meningitis incidence
Endpoint domain: Adverse events/effects
Primary endpoint: MMP expression in vascular malformation tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of Participants Experiencing Adverse Events defined as Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerable dose of chidamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerable dose (MTD) and recommended Phase 2 dose (RP2D) of chidamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensibility of [18F] ODS2004436
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of [18F] ODS2004436
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-termed Fractal Scaling Exponent (Alpha 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in ulcer area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Average Daily Frequency of Moderate to Severe VMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Average Daily Severity Score of Mild to Severe VMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced ≥1 Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients meeting NICE recommendations on risk factor modifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of health related behaviour
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Aluminum content of sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spermatic DNA fragmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathologic examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Mean GH < 1 g/L and IGF-1 < ULN at Week 36
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Standard Uptake Value (SUV) Area Under the Curve (AUC) - Bladder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard Uptake Value (SUV) Area Under the Curve (AUC) - Gallbladder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard Uptake Value (SUV) Area Under the Curve (AUC) - Heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard Uptake Value (SUV) Area Under the Curve (AUC) - Kidneys
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard Uptake Value (SUV) Area Under the Curve (AUC) - Liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventricular Tachyarrhythmia episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose of lenalidomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-limiting toxicity of lenalidomide
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Activity Score (CAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hrHPV self-sampling test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization for all cardio-vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Arthropathy (Cumulative)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of Nervous System Events (Cumulative)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Use of Rescue Medications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Hearing Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Physical Activity Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area under the curve (AUC) of VEGF-A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Union and healing of Calcaneus Fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Had One or More Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Completion rate of supervised physical therapy exercise sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: maxillary growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First New Flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (0-100mm VAS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Adverse Events (AE), Death and Serious Adverse Events (24 Weeks Overall)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Adverse Events (AE), Death and Serious Adverse Events (72 Weeks Overall)
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of favipiravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of favipiravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in biomarker assays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent change in Tumor Infiltrating Lymphocytes (TILs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Distance travelled during 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for Preoxygenation to FEO2=90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Pain Burden
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Anti-CCP Antibody positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immediate and early post-operative complication
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Who Experienced at Least 1 Treatment Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Who Experienced at Least 1 Serious Treatment Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Bone mineral density increase at lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of potentially inappropriate prescriptions at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients receiving ramosetron or palonosetron
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: severity of postoperative nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Achieving Donor Cell Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of the EndoFaster test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma malondialdehyde (MDA) postprandial measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Preterm delivery <34 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Dietary energy compensation as measured by weight changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (QOL) change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disabilities of arm, shoulder, hand change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Erectile function change
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Impact of Event Scale - Revised (IES-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: General Anxiety Disorder (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ilivia Family Related SADE-free Rate Through 3 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Plexa Related SADE-free Rate Through 6 Months
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of wide pulse pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in motor evoked potential (MEP) amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in prescription of antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incremental Recovery for plasma Factor VIII
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of increase in CA 125 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of increase in other tumor markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ADAS-Cog
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in dysfunctional discipline practices
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in physical abuse potential
Endpoint domain: Adverse events/effects
Primary endpoint: Virus negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical response rate at post-therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological response at post-therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean Number of Adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: anxiety (clinical recovery)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: depression (clinical recovery)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: social functioning (clinical recovery)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Area under the plasma concentration-time curve (AUC) from Time 0 to infinity of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Half Life of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Recurrent VT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiovascular Rehospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Fluid intake 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain oxygen extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of fungal infection
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate for each strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P2Y12 Reaction Unit (PRU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total duration of opioid treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cross-sectional area of the rectus femoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: A1C Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transplant-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with CTX possibility in Neurology Clinics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with CTX possibility in Pediatric Metabolism Clinics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Any Grade 3-5 Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic fungal infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total Symptom Score (TSS) Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Changes in Functional Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative GIQLI score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hepatic de novo lipogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility (recruitment and retention)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUC(0-t')
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of tasks in the application
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Amenorrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Lipid peroxidation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: MDRD GFR < 30 ml/min/1.73 meter squared
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Average Daily Endometriosis Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient breath alcohol concentration (BrAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful EGD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Neovascularisation reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-∞) and AUC(0-t) of total drug-related material in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of total drug-related material in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary and faecal cumulative excretion as a percentage of the total radioactive dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of procedures performed on enrolled patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Absolute Relative Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bronchial hyperactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in NYHA WHO Functional Class
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right and left heart catheterization measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Echocardiograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: OR duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hernia Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total Cost of Surgery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Permanent virological efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average daily narcotic consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient-reported Symptoms Measured by the 8-point Lee Eye Subscale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Patient-reported Symptoms as Measured by the Ocular Surface Disease Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Patient-reported Symptoms as Measured by the 11-point Eye Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: amount of activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Timed up and go test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N100 wave amplitude in µv
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: P300 wave amplitude in µv
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Plasma levels of TMC435, midazolam and cocktail compounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H. pylori gastric load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: First time and appropriately timed clinical breast exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: First time and appropriately timed mammogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: First time and appropriately timed pap test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: incidence of difficult regional and general anesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of recombinant human growth hormone
Endpoint domain: Adverse events/effects
Primary endpoint: Axial Elongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nicotine biodistribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nicotine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients attaining ABC targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Daily Sedentary Time Accumulated in Bouts Greater Than or Equal to 30 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Daily Number of Sedentary Breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ESL retention rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention